Search
Hoth Therapeutics Inc
HOTHAdd to Watchlist
1.360USD
0.0000.00%
Market hours （ET）Quotes delayed by 15 min
21.02MMarket Cap
LossP/E TTM
More Details of Hoth Therapeutics Inc Company
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. The Company is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT), and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The Company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for obesity, and obesity-related diseases and conditions (HT-VA).
Hoth Therapeutics Inc Info
Ticker SymbolHOTH
Company nameHoth Therapeutics Inc
IPO dateFeb 15, 2019
CEOKnie (Robb)
Number of employees2
Security typeOrdinary Share
Fiscal year-endFeb 15
Address1177 Avenue Of The Americas
CityNEW YORK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10036
Phone16467562997
Websitehttps://hoththerapeutics.com/
Ticker SymbolHOTH
IPO dateFeb 15, 2019
CEOKnie (Robb)
Company Executives of Hoth Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Jeff Pavell
Dr. Jeff Pavell
Independent Director
Independent Director
5.08K
--
Mr. Wayne Linsley
Mr. Wayne Linsley
Independent Director
Independent Director
134.00
--
Mr. Robb Knie
Mr. Robb Knie
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. David Sarnoff
Mr. David Sarnoff
Independent Director
Independent Director
--
--
Mr. David S. Briones
Mr. David S. Briones
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Chris Camarra
Mr. Chris Camarra
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Jeff Pavell
Dr. Jeff Pavell
Independent Director
Independent Director
5.08K
--
Mr. Wayne Linsley
Mr. Wayne Linsley
Independent Director
Independent Director
134.00
--
Mr. Robb Knie
Mr. Robb Knie
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. David Sarnoff
Mr. David Sarnoff
Independent Director
Independent Director
--
--
Mr. David S. Briones
Mr. David S. Briones
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Chris Camarra
Mr. Chris Camarra
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Hoth Therapeutics Inc?
The top five shareholders of Hoth Therapeutics Inc are: Dr. Jeff Pavell
How many institutions hold shares of Hoth Therapeutics Inc (HOTH)?
As of 2026Q1, 43 institutions hold shares of Hoth Therapeutics Inc, with a combined market value of approximately 1.30M, accounting for 6.79% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -245182.00.